Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 15;76(21):1777-1787.
doi: 10.1093/ajhp/zxz196.

A systematic overview of systematic reviews evaluating interventions addressing polypharmacy

Laura J Anderson  1 , Jeffrey L Schnipper  2 , Teryl K Nuckols  1 , Rita Shane  3 , Catherine Sarkisian  4 , Michael M Le  5 , Joshua M Pevnick  1 ; Members of the PHARM-DC group
Collaborators, Affiliations

A systematic overview of systematic reviews evaluating interventions addressing polypharmacy

Laura J Anderson et al. Am J Health Syst Pharm. .

Abstract

Purpose: To systematically evaluate and summarize evidence across multiple systematic reviews (SRs) examining interventions addressing polypharmacy.

Summary: MEDLINE, the Cochrane Database of Systematic Reviews, and the Database of Abstracts of Reviews of Effects (DARE) were searched for SRs evaluating interventions addressing polypharmacy in adults published from January 2004 to February 2017. Two authors independently screened, appraised, and extracted information. SRs with Assessment of Multiple Systematic Reviews (AMSTAR) scores below 8 were excluded. After extraction of relevant conclusions from each SR, evidence was summarized and conclusions compared. Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess evidence quality. Six SRs met the inclusion criteria, 4 of which used meta-analytic pooling. Five SRs focused on older adults. Four were not restricted to any specific disease type, whereas 1 focused on proton pump inhibitors and another focused on patients with severe dementia. Care settings and measured outcomes varied widely. SRs examining the impact on patient-centered outcomes, including morbidity, mortality, patient satisfaction, and utilization, found inconsistent evidence regarding the benefit of polypharmacy interventions, but most concluded that interventions had either null or uncertain impact. Two SRs assessing medication appropriateness found very low-quality evidence of modest improvements with polypharmacy interventions.

Conclusion: An overview of SRs of interventions to address polypharmacy found 6 recent and high-quality SRs, mostly focused on older adults, in which both process and outcome measures were used to evaluate interventions. Despite the low quality of evidence in the underlying primary studies, both SRs that assessed medication appropriateness found evidence that polypharmacy interventions improved it. However, there was no consistent evidence of any impact on downstream patient-centered outcomes such as healthcare utilization, morbidity, or mortality.

Keywords: aged; deprescriptions; polypharmacy; review; systematic review.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
PRISMA flow diagram.
See this image and copyright information in PMC

References

    1. Forster AJ, Murff HJ, Peterson JF et al. . The incidence and severity of adverse events affecting patients after discharge from the hospital. Ann Intern Med. 2003; 138(3):161-7. - PubMed
    1. Kripalani S, Roumie CL, Dalal AK et al. . Effect of a pharmacist intervention on clinically important medication errors after hospital discharge: a randomized trial. Ann Intern Med. 2012; 157(1):1-10. - PMC - PubMed
    1. Tsilimingras D, Schnipper J, Duke A et al. . Post-discharge adverse events among urban and rural patients of an urban community hospital: a prospective cohort study. J Gen Intern Med. 2015; 30(8):1164-71. - PMC - PubMed
    1. Burns JM, Sneddon I, Lovell M et al. . Elderly patients and their medication: a post-discharge follow-up study. Age Ageing. 1992; 21(3):178-81. - PubMed
    1. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc. 2001; 41(2):192-9. - PubMed

Publication types

MeSH terms